In the shadow of headlines about the mental health crisis and the limits of current psychiatric care, one small biotech is making quiet but meaningful progress. Enveric Biosciences (NASDAQ: ENVB) announced this week that its lead drug candidate, EB-003, demonstrated a rapid therapeutic effect in a well-validated preclinical model for post-traumatic stress disorder (PTSD)—a condition that affects nearly 13 million Americans each year.